A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

This study is testing a CAR T-cell therapy called ciltacabtagene autoleucel (cilta-cel) in people with newly diagnosed multiple myeloma who are not candidates for high-dose chemotherapy with a stem cell transplant. Multiple myeloma is a blood cancer affecting plasma cells in the bone marrow. **You may be eligible if...** - You have been newly diagnosed with multiple myeloma - Your disease is measurable by specific blood or urine protein markers - You are not eligible for high-dose chemotherapy with stem cell transplant due to age or other health conditions **You may NOT be eligible if...** - You have already received substantial prior treatment for multiple myeloma - You have significant organ dysfunction that makes this therapy unsafe - You have conditions that exclude you from CAR T-cell therapy (such as active serious infection) Talk to your doctor to see if this trial is right for you.